Chlorotoxin-conjugated graphene oxide for targeted delivery of an anticancer drug

96Citations
Citations of this article
89Readers
Mendeley users who have this article in their library.

Abstract

Current chemotherapy for glioma is rarely satisfactory due to low therapeutic efficiency and systemic side effects. We have developed a glioma-targeted drug delivery system based on graphene oxide. Targeted peptide chlorotoxin-conjugated graphene oxide (CTX-GO) sheets were successfully synthesized and characterized. Doxorubicin was loaded onto CTX-GO (CTX-GO/DOX) with high efficiency (570 mg doxorubicin per gram CTX-GO) via noncovalent interactions. Doxorubicin release was pH-dependent and showed sustained-release properties. Cytotoxicity experiments demonstrated that CTX-GO/DOX mediated the highest rate of death of glioma cells compared with free doxorubicin or graphene oxide loaded with doxorubicin only. Further, conjugation with chlorotoxin enhanced accumulation of doxorubicin within glioma cells. These findings indicate that CTX-GO is a promising platform for drug delivery and provide a rationale for developing a glioma-specific drug delivery system. © 2014 Sun et al.

Cite

CITATION STYLE

APA

Wang, H., Gu, W., Xiao, N., Ye, L., & Xu, Q. (2014). Chlorotoxin-conjugated graphene oxide for targeted delivery of an anticancer drug. International Journal of Nanomedicine, 9(1), 1433–1442. https://doi.org/10.2147/IJN.S58783

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free